簡介
五國專利的PI高分子網孔，製成高效網式噴霧器，可搭配生理食鹽水與醫師處方藥液稀釋痰液及治療肺部疾病，適用於慢性呼吸道疾病及亞健康族群的居家與醫療院所呼吸照護。
藥物霧化遞送
回到技術應用
產品相簿
詳細介紹
呼吸道健康管理
肺部疾病是最常見的健康異常之一，有無數的患者需要長期健康管理達到最佳照護。 
生活品質改善
致力於提供更好的肺部疾病護理來幫助病患。
霧化給藥專家
運用核心技術發展霧化給藥方式，為需求者設計最佳的解决方案。 
關於帕基艾兒 POCKET AIR®
帕基艾兒 POCKET AIR® 是藉由微邦科技特有的高分子塑膠微孔片(PI)與微孔振動核心技術(Mesh)延伸的醫療級品牌。
產品介紹
.jpg)
得獎榮耀
期刊論文
Published in: Pediatric Respirology and Critical Care Medicine
I-Ping Wu, Ming-Yi Chien, Hsiu-Feng Hsiao, Eric YT Chen, Yun-Yueh Liu, Chang-Wei Chou, Shen-Hao Lai
Abstract
Study design
...shown in Figure 1. SVN and VMN used in this study were from Gale Med Nebulizer Kits (GaleMed Corporation, Taipei, Taiwan) and PocketAir™ Portable Nebulizer (MicroBase Technology, Taoyuan, Taiwan), respectively. The delivery of hypertonic saline aerosol prescription was designed as 4 ml of 3% saline solution (three times a day) using nebulizer.
Study design
...shown in Figure 1. SVN and VMN used in this study were from Gale Med Nebulizer Kits (GaleMed Corporation, Taipei, Taiwan) and PocketAir™ Portable Nebulizer (MicroBase Technology, Taoyuan, Taiwan), respectively. The delivery of hypertonic saline aerosol prescription was designed as 4 ml of 3% saline solution (three times a day) using nebulizer.
Published in: Biomicrofluidics
Chun-Kai Lin, Yuan-Yuan Hsiao, Pulak Nath, and Jen-Huang Huang
Abstract
Exposure system setup
…The aerosols were generated from a commercially available vibrating mesh nebulizer (MBPN002, Pocket Air). The vibrating mesh approximately measured 3.4 μm to ensure that the generated aerosol demonstrated a mass median aerodynamic diameter (MMAD) measuring approximately 4.2 μm (Fig. S1 in the supplementary material)…
Exposure system setup
…The aerosols were generated from a commercially available vibrating mesh nebulizer (MBPN002, Pocket Air). The vibrating mesh approximately measured 3.4 μm to ensure that the generated aerosol demonstrated a mass median aerodynamic diameter (MMAD) measuring approximately 4.2 μm (Fig. S1 in the supplementary material)…
Published in: medRXiv
Michael V. Dubina, Veronika V. Gomonova, Anastasia E. Taraskina, Natalia V. Vasilyeva, Sergey A. Sayganov
Abstract
Intervention
The combined medication was self-administered as an aerosol using a personal handheld nebulizer (Nebzmart MBPN002; MicroBase Technology, Taiwan) driven by compressed air at 0.25 ml/min. Eligible participants received the study treatment for 14 days; they were instructed to perform four inhalation sessions per day with 4 h in between sessions.
Intervention
The combined medication was self-administered as an aerosol using a personal handheld nebulizer (Nebzmart MBPN002; MicroBase Technology, Taiwan) driven by compressed air at 0.25 ml/min. Eligible participants received the study treatment for 14 days; they were instructed to perform four inhalation sessions per day with 4 h in between sessions.
Published in: Therapeutic Advances in Respiratory Disease
Deyu Zhao, Dehui Chen, Ling Li, YingXue Zou, Yunxiao Shang, Chonglin Zhang, Li Zhang, Jiahua Pan, Qiang Chen, Tao Ai and Qian Ni
Abstract
Methods
Study design
The CARE study [ClinicalTrials.gov identifier: NCT03156998] was a multicentre, prospective, observational study across 12 tertiary hospitals in China. Subjects were consecutively enrolled and asthma medication was prescribed as per routine clinical practice. A portable nebulizer device POCKET AIR® MBPN002 (Microbase Technology Corp, Taiwan) for home use was sup-plied by the investigators for the study duration...
Methods
Study design
The CARE study [ClinicalTrials.gov identifier: NCT03156998] was a multicentre, prospective, observational study across 12 tertiary hospitals in China. Subjects were consecutively enrolled and asthma medication was prescribed as per routine clinical practice. A portable nebulizer device POCKET AIR® MBPN002 (Microbase Technology Corp, Taiwan) for home use was sup-plied by the investigators for the study duration...
Poster accepted for DDL 2019
Chen-Hsiang Sang, Wei Zhe Tsai, Wen Chieh Chiang & Liang Rern Kung
Department of R&D, Medical Division, MicroBase Technology Corp., Bade District, Taoyuan City, Taiwan
Abstract
Knowing and understanding the performance of vibrating mesh nebulizers is critical since it is related to the efficacy of inhalation drug delivery. Cleaning process to avoid cross-contamination of different drugs and mesh clogging are two disadvantages mostly being recognized among vibrating mesh nebulizers. The present study compared the Mass Median Aerodynamic Diameter (MMAD), Geometric Standard Deviation (GSD), Fine Particle Fraction percent less than 5 μm (FPF (<5 μm)), and vibration modal pattern during nebulization among two types of polymer-based MicroBase Technology (MBTC) Pocket Air® nebulizers, newly launched contact-triggered vibrating mesh (CTVM) and commercially available Portable Nebulizer (NEB); these were compared with Aerogen® Solo;PARI VELOX® and PARI eFlow® rapid (The 5 nebulizers are shown below).
Knowing and understanding the performance of vibrating mesh nebulizers is critical since it is related to the efficacy of inhalation drug delivery. Cleaning process to avoid cross-contamination of different drugs and mesh clogging are two disadvantages mostly being recognized among vibrating mesh nebulizers. The present study compared the Mass Median Aerodynamic Diameter (MMAD), Geometric Standard Deviation (GSD), Fine Particle Fraction percent less than 5 μm (FPF (<5 μm)), and vibration modal pattern during nebulization among two types of polymer-based MicroBase Technology (MBTC) Pocket Air® nebulizers, newly launched contact-triggered vibrating mesh (CTVM) and commercially available Portable Nebulizer (NEB); these were compared with Aerogen® Solo;PARI VELOX® and PARI eFlow® rapid (The 5 nebulizers are shown below).
- Contact-triggered vibratingmesh (CTVM, Microbase Technology Pocket Air®)
- Portable nebulizer (NEB, Microbase Technology Pocket Air®)
- Solo (Aerogen®)
- VELOX® (PARI)
- eFlow® Rapid (PARI)
Poster accepted for DDL 2018
Chen-Hsiang Sang, Shih-Cherng Lin, Huang-Fei Chen, Hsin-Hua Tseng & Hsiao-Hui Lo
Department of R&D, Medical Division, MicroBase Technology Corp., Bade District, Taoyuan City, Taiwan
Abstract
The performance of vibrating mesh nebulizers is crucial, since it is related to the efficacy of inhalative drug delivery. The presented study compares the distribution of droplet size, nebulization output rate, and vibration modal pattern during nebulization of polymer-based mesh nebulizer from MicroBase Technology (MBTC) to that of metal-based mesh nebulizer from Aerogen® Solo, and PARI VELOX®
. The revealed results demonstrated that these nebulizers generated relatively similar particle diameter distribution. The volumetric-median-diameter of MBTC nebulizer, Aerogen® Solo, and PARI VELOX® were 5.11±0.44 μm, 5.02±0.67 μm, and 4.11±0.30 μm, respectively. The averaged output rate of the nebulizers from MBTC was 0.73±0.15 mL/min for normal saline (0.9%), which is 1.4 times greater than Aerogen® Solo (0.53±0.12 mL/min), whilst similar to that of PARI VELOX® (0.76±0.18 mL/min). Moreover, these three nebulizers showed similar modal pattern during operations giving a comparable resonant frequency between MBTC and Aerogen® Solo (125.9 kHz vs. 128.2 kHz, respectively), but slightly lower than PARI VELOX® (160.0 kHz). Ample design and application with the implemented of polymer-based mesh nebulizer would be prospectively expected. Further studies to take the advantage of MBTC nebulizer as liquid medications delivery is under assessment.
The performance of vibrating mesh nebulizers is crucial, since it is related to the efficacy of inhalative drug delivery. The presented study compares the distribution of droplet size, nebulization output rate, and vibration modal pattern during nebulization of polymer-based mesh nebulizer from MicroBase Technology (MBTC) to that of metal-based mesh nebulizer from Aerogen® Solo, and PARI VELOX®
. The revealed results demonstrated that these nebulizers generated relatively similar particle diameter distribution. The volumetric-median-diameter of MBTC nebulizer, Aerogen® Solo, and PARI VELOX® were 5.11±0.44 μm, 5.02±0.67 μm, and 4.11±0.30 μm, respectively. The averaged output rate of the nebulizers from MBTC was 0.73±0.15 mL/min for normal saline (0.9%), which is 1.4 times greater than Aerogen® Solo (0.53±0.12 mL/min), whilst similar to that of PARI VELOX® (0.76±0.18 mL/min). Moreover, these three nebulizers showed similar modal pattern during operations giving a comparable resonant frequency between MBTC and Aerogen® Solo (125.9 kHz vs. 128.2 kHz, respectively), but slightly lower than PARI VELOX® (160.0 kHz). Ample design and application with the implemented of polymer-based mesh nebulizer would be prospectively expected. Further studies to take the advantage of MBTC nebulizer as liquid medications delivery is under assessment.Poster accepted for ATS 2018
Hsiang-Ling Chen1, Chia-Chen Huang1, Huang-Fei Chen1, Chi-Shan Hung1, Ting-Kai Tsai1,Hui-Ling Lin2, Eric Y.T. Chen1
- R&D Department, MicroBase Technology Corp, Taoyuan, Taiwan
- Department of Respiratory Therapy, Chang Gung University, Taoyuan, Taiwan
Abstract
Aerosol therapy of antibiotics and corticosteroids has become an emergent trend in clinical practice. However, studies have shown that a large variation exists in medication delivery efficiency among different nebulization systems. Herein we compared the functional performance of two vibrating-mesh and a jet nebulizers when atomizing colistimethate sodium and budesonide.
Aerosol therapy of antibiotics and corticosteroids has become an emergent trend in clinical practice. However, studies have shown that a large variation exists in medication delivery efficiency among different nebulization systems. Herein we compared the functional performance of two vibrating-mesh and a jet nebulizers when atomizing colistimethate sodium and budesonide.
Poster accepted for ATS 2018
Chang-Wei Chou1, Eric Y.T. Chen1, Yun-Yueh Liu1, I-Ping Wu2, Ming-Yi Chien3,Hsiu-Feng Hsiao2, and Shen-Hao Lai4
- R&D, MicroBase Technology Corporation, Bade District, Taoyuan City, Taiwan,
- Department of Respiratory Therapy, Chang Gung Memorial Hospital, Linkou Branch, Chang Gung University, Taoyuan City,
- Department of Respiratory Therapy, Chang Gung Memorial Hospital, Keelung Branch, Keelung City, Taiwan,
- Pediatrics, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan City, Taiwan
Abstract
By convention, treatment for acute bronchiolitis infants has been predominantly confined to aerosol therapy delivered by small-volume jet nebulizer (SVN). However, such therapy suffers from concomitant inconsistencies such as, but not limited to, varying drug concentration, drug temperature variation and excess noise. Whether a vibrating-mesh nebulizer could circumvent traditional limitations yet alleviate symptoms was unclear. Herein, our randomized clinical trial revealed that a portable vibrating-mesh nebulizer (Pocket Air) had achieved comparable end-points when administering hypertonic saline and could potentially serve as an improved therapeutic approach for future treatments.
By convention, treatment for acute bronchiolitis infants has been predominantly confined to aerosol therapy delivered by small-volume jet nebulizer (SVN). However, such therapy suffers from concomitant inconsistencies such as, but not limited to, varying drug concentration, drug temperature variation and excess noise. Whether a vibrating-mesh nebulizer could circumvent traditional limitations yet alleviate symptoms was unclear. Herein, our randomized clinical trial revealed that a portable vibrating-mesh nebulizer (Pocket Air) had achieved comparable end-points when administering hypertonic saline and could potentially serve as an improved therapeutic approach for future treatments.
Poster accepted for RDD (Respiratory Drug Delivery) 2018
Ssu-Ching Hsiao, Chang-Wei Chou, Ting-Kai Tsai, Chih-Wei Lu, Chun-Chin Hsu, Shih-Wen Li, and Eric Y.T. Chen MicroBase Technology Corporation, R&D, Taoyuan City, Taiwan
Abstract
Although traditional vibrating mesh nebulizers overcome many of the disadvantage of small volume jet nebulizer, which include being noisy, bulky, exhibiting poor portability, and being inefficient [1]. They are prone to mesh clogging, require inconvenient cleaning/disinfection processes, and are expensive [2]. During repetitive nebulization, the microscopic holes in the vibrating mesh module may be easily obstructed by suspension-based formulations, dust, or other particles bigger than the aperture size. The more often such a nebulizer is used, the more likely the holes of the mesh will be blocked. A contact-triggered vibrating mesh nebulization system, MicroBase μSMI (Figure 1), which utilizes a cost-effective disposable medical cup, was developed to overcome the limitations of traditional vibrating mesh systems. In this study, we compared the aerosol characteristics of a suspension-type drug formulation delivered with MicroBase μSMI to those obtained using a series of commercially available vibrating mesh nebulizers.
Although traditional vibrating mesh nebulizers overcome many of the disadvantage of small volume jet nebulizer, which include being noisy, bulky, exhibiting poor portability, and being inefficient [1]. They are prone to mesh clogging, require inconvenient cleaning/disinfection processes, and are expensive [2]. During repetitive nebulization, the microscopic holes in the vibrating mesh module may be easily obstructed by suspension-based formulations, dust, or other particles bigger than the aperture size. The more often such a nebulizer is used, the more likely the holes of the mesh will be blocked. A contact-triggered vibrating mesh nebulization system, MicroBase μSMI (Figure 1), which utilizes a cost-effective disposable medical cup, was developed to overcome the limitations of traditional vibrating mesh systems. In this study, we compared the aerosol characteristics of a suspension-type drug formulation delivered with MicroBase μSMI to those obtained using a series of commercially available vibrating mesh nebulizers.
Poster accepted for DDL (Drug Delivery to the Lungs Conference) 2017
Chia-Chen Huang1, Hsiang-Ling Chen1, Chi-Shan Hung1, Eric Y.T. Chen1, Hui-Ling Lin2
1MicroBase Technology Corp, 756, Jiadong Road, Bade, Taoyuan, 33464, Taiwan
2Chang Gung University, 261, Wenhua 1st Road, Guishan, Taoyuan, 3302, Taiwan
Abstract
Successful delivery of aerosolized medication within mechanical ventilation (MV) necessitates an efficient vibrating mesh nebulizer connected to a well-designed T-adaptor that is subsequently conjoined to the inlet of a heated humidifier in a closed ventilator circuit. The aim of this study was to compare MicroBase mechanical ventilator nebulizer plus μMVN+ (Microbase Tech. Corp., Taiwan) to currently used nebulizers during MV. A Puritan Bennet 760 ventilator was set to adult parameters (TV 600mL, 16 breaths/min, PEEP 5cm H2O) and connected to an endotracheal tube (ETT) with a filter to a passive test lung. A unit dose of salbutamol (Ventolin, 5 mg / 2.5 mL, GlaxoSmithKline) or budesonide (Pulmicort, 1.0 mg / 2.0 mL, AstraZeneca) was individually added to 5 aerosol generators, namely μMVN+4.0 (MMAD 4.0μm), μMVN+3.0 (MMAD 3.0μm), μMVN+2.0 (MMAD 2.0μm), Aerogen Solo (Aerogen Ltd., Ireland) and jet nebulizer JN (Galemed Corp.,Taiwan). All aerosol generators were placed at the inlet of a heated humidifier. Aerogen Solo was connected to the Aerogen T-adaptor and JN was connected to a standard T-adaptor. All three μMVN+ were connected to the MicrosBase Tech. Corp. second generation (MBTC-SG) T-adaptor. Drug collected on filter was eluted and analyzed with spectrophotometer at a wavelength of 276nm for salbutamol and 254nm for budesonide (n=5). The inhaled dose % of all μMVN+ which connected to MBTC-SG T-adaptor was significantly greater than Aerogen Solo and JN (p<0.001) for both drugs. Inhaled dose % of salbutamol of all devices was significantly greater than that of budesonide (p<0.001). The newly designed of μMVN+ with MBTC-SG T-adaptor enhanced aerosol drug delivery efficiency possibly by reducing aerosol impaction and condensation during nebulization.
Successful delivery of aerosolized medication within mechanical ventilation (MV) necessitates an efficient vibrating mesh nebulizer connected to a well-designed T-adaptor that is subsequently conjoined to the inlet of a heated humidifier in a closed ventilator circuit. The aim of this study was to compare MicroBase mechanical ventilator nebulizer plus μMVN+ (Microbase Tech. Corp., Taiwan) to currently used nebulizers during MV. A Puritan Bennet 760 ventilator was set to adult parameters (TV 600mL, 16 breaths/min, PEEP 5cm H2O) and connected to an endotracheal tube (ETT) with a filter to a passive test lung. A unit dose of salbutamol (Ventolin, 5 mg / 2.5 mL, GlaxoSmithKline) or budesonide (Pulmicort, 1.0 mg / 2.0 mL, AstraZeneca) was individually added to 5 aerosol generators, namely μMVN+4.0 (MMAD 4.0μm), μMVN+3.0 (MMAD 3.0μm), μMVN+2.0 (MMAD 2.0μm), Aerogen Solo (Aerogen Ltd., Ireland) and jet nebulizer JN (Galemed Corp.,Taiwan). All aerosol generators were placed at the inlet of a heated humidifier. Aerogen Solo was connected to the Aerogen T-adaptor and JN was connected to a standard T-adaptor. All three μMVN+ were connected to the MicrosBase Tech. Corp. second generation (MBTC-SG) T-adaptor. Drug collected on filter was eluted and analyzed with spectrophotometer at a wavelength of 276nm for salbutamol and 254nm for budesonide (n=5). The inhaled dose % of all μMVN+ which connected to MBTC-SG T-adaptor was significantly greater than Aerogen Solo and JN (p<0.001) for both drugs. Inhaled dose % of salbutamol of all devices was significantly greater than that of budesonide (p<0.001). The newly designed of μMVN+ with MBTC-SG T-adaptor enhanced aerosol drug delivery efficiency possibly by reducing aerosol impaction and condensation during nebulization.
Poster accepted for 2017 Pediatric Respirology and Critical Care Medicine
I-Ping Wu, Ming-Yi Chien, Hsiu-Feng Hsiao, Eric YT Chen, Yun-Yueh Liu, Chang-Wei Chou, Shen-Hao Lai
Abstract
Bronchiolitis is a disease that is predominantly caused by the infection of peripheral airway due to respiratory syncytial virus (RSV). The occurrence is highly prevalent among childhood stage with seasonal outbreak peak during fall and spring. Treatment of bronchiolitis Aerosolizing hypertonic saline using small-volume jet nebulizer (SVN) remains as one of the effective therapies to alleviate symptoms in infants with acute bronchiolitis. However, such approach not only restraints treatment to hospitalization and can irritate patients with loud noise. It is Materials and Methods: Herein we showed that a vibrating mesh nebulizer (VMN) offered quiet delivery and undisturbed nebulization yet harnessed similar improvement in clinical symptoms in contrast with SVN when treating hospitalized infants with acute bronchiolitis. Results: A total of 64 hospitalized infants (<12 months of age) with acute bronchiolitis were enrolled. Subjects were randomly assigned to SVN (n=32) and VMN (n=32) groups and had received the same aerosol treatment protocol during hospitalization. Besides respiratory rate, the initial overall severity score; hospital stay duration; and intravascular-line day for both groups (SVN vs VMN) were similar. The data were 4.30±1.44 vs 4.92±1.3; 3.97±1.88 vs 3.94±1.66 days; 2.31±1.47 vs 2.16±1.46 days correspondingly. However, a higher satisfaction score (4.8/5) was shown in a corresponding questionnaire indicating user preference in VMN due to enhanced portability, ease of clean and operation, and less-noise. These advantages could potentially facilitate bronchiolitis treatment and follow-up maintenance at home. Conclusion: In sum, the treatment outcome for infants with acute bronchiolitis was equivalent between SVN and VMN. Easy portability and simple operation features of VMN may present a much favored therapeutic option for home care users.
Bronchiolitis is a disease that is predominantly caused by the infection of peripheral airway due to respiratory syncytial virus (RSV). The occurrence is highly prevalent among childhood stage with seasonal outbreak peak during fall and spring. Treatment of bronchiolitis Aerosolizing hypertonic saline using small-volume jet nebulizer (SVN) remains as one of the effective therapies to alleviate symptoms in infants with acute bronchiolitis. However, such approach not only restraints treatment to hospitalization and can irritate patients with loud noise. It is Materials and Methods: Herein we showed that a vibrating mesh nebulizer (VMN) offered quiet delivery and undisturbed nebulization yet harnessed similar improvement in clinical symptoms in contrast with SVN when treating hospitalized infants with acute bronchiolitis. Results: A total of 64 hospitalized infants (<12 months of age) with acute bronchiolitis were enrolled. Subjects were randomly assigned to SVN (n=32) and VMN (n=32) groups and had received the same aerosol treatment protocol during hospitalization. Besides respiratory rate, the initial overall severity score; hospital stay duration; and intravascular-line day for both groups (SVN vs VMN) were similar. The data were 4.30±1.44 vs 4.92±1.3; 3.97±1.88 vs 3.94±1.66 days; 2.31±1.47 vs 2.16±1.46 days correspondingly. However, a higher satisfaction score (4.8/5) was shown in a corresponding questionnaire indicating user preference in VMN due to enhanced portability, ease of clean and operation, and less-noise. These advantages could potentially facilitate bronchiolitis treatment and follow-up maintenance at home. Conclusion: In sum, the treatment outcome for infants with acute bronchiolitis was equivalent between SVN and VMN. Easy portability and simple operation features of VMN may present a much favored therapeutic option for home care users.
Poster accepted for AARC (American Association for Respiratory Care ) Congress 2017
Hui-Ling Lin1 ,3RRT MSc FAARC, Yu-Yao Kao2RT Bs, Eric Y.T. Chen2PhD
1Department of Respiratory Therapy, Chang Gung University, Taoyuan, Taiwan
2R&D Department, MicroBase Technology Corp, Taoyuan, Taiwan
3Respiratory Therapy, Chiayi Chang Gung Memorial Hospital, Chiayi, Taiwan
Abstract
Successful delivery of aerosolized medication within mechanical ventilation (MV) necessitates an efficient vibrating mesh nebulizer connected to a well-designed T-adaptor that is subsequently conjoined to the inlet of a heated humidifier in a closed ventilator circuit. However, many traditional T-adaptors suffer from significant aerosol impaction, thus reducing drug delivery efficacy. This study compared aerosol drug delivery outcome between conventional and reengineered T-adaptors when fitted with different vibrating mesh nebulizers during adult MV.
Key word: mechanical ventilation; aerosol drug delivery; vibrating mesh nebulizers; T-adaptor; bronchodilator.
Successful delivery of aerosolized medication within mechanical ventilation (MV) necessitates an efficient vibrating mesh nebulizer connected to a well-designed T-adaptor that is subsequently conjoined to the inlet of a heated humidifier in a closed ventilator circuit. However, many traditional T-adaptors suffer from significant aerosol impaction, thus reducing drug delivery efficacy. This study compared aerosol drug delivery outcome between conventional and reengineered T-adaptors when fitted with different vibrating mesh nebulizers during adult MV.
Key word: mechanical ventilation; aerosol drug delivery; vibrating mesh nebulizers; T-adaptor; bronchodilator.
Poster accepted for CTS ( Chinese Thoracic Societ ) Congress 2017
Yu-Yao Kao1, Chia-Chen Huang1, Chi-Shan Hung1, Hsian-Ling Chen1, Eric Y.T. Chen1, Hui-Ling Lin2
1R&D Department, MicroBase Technology Corp, Taoyuan, Taiwan ZIP: 33464
2Department of Respiratory Therapy, Chang Gung University, Taoyuan, Taiwan ZIP: 33302
Abstract
Successful delivery of aerosolized medication within mechanical ventilation (MV) necessitates an efficient nebulizer connected to a welldesigned T-adaptor that is subsequently conjoined to the inlet of a heated humidifier in a closed ventilator circuit. However, small volume jet nebulizers (SVN) severely suffer from general inefficiency due to high residual volume and significant aerosol impaction at a conjoined Tadaptor. This study compared aerosol drug delivery efficiency of MicroBase Mechanical Ventilation Nebulizer Plus (μMVN+), novel polymeric vibrating-mesh nebulizer, and jet nebulizer (SVN), capillary action nebulizer with a specially engineered T-adaptor during adult MV.
Successful delivery of aerosolized medication within mechanical ventilation (MV) necessitates an efficient nebulizer connected to a welldesigned T-adaptor that is subsequently conjoined to the inlet of a heated humidifier in a closed ventilator circuit. However, small volume jet nebulizers (SVN) severely suffer from general inefficiency due to high residual volume and significant aerosol impaction at a conjoined Tadaptor. This study compared aerosol drug delivery efficiency of MicroBase Mechanical Ventilation Nebulizer Plus (μMVN+), novel polymeric vibrating-mesh nebulizer, and jet nebulizer (SVN), capillary action nebulizer with a specially engineered T-adaptor during adult MV.
Poster accepted for ERS (European Respiratory Society ) International Congress 2017
Yu-Yao Kao1, Chia-Chen Huang1, Chi-Shan Hung1, Eric Y.T. Chen1*, Hui-Ling Lin2*
1R&D Department, MicroBase Technology Corp, Taoyuan City, Taiwan
2Department of Respiratory Therapy, Chang Gung University, Taoyuan City, Taiwan
Abstract
Aerosol drug delivery through small volume nebulizer (SVN) in mechanical ventilation is widely utilized in treating various respiratory disorders; however, studies have also shown concomitant pitfall in delivery inefficiency. The aim of the study was to compare our novel polymeric vibrating-mesh nebulizer (μMVN+) to currently used aerosol devices during MV. Key word: aerosol drug delivery; vibrating-mesh nebulizer; small volume jet nebulizer; bronchodilator; mechanical ventilation.
Aerosol drug delivery through small volume nebulizer (SVN) in mechanical ventilation is widely utilized in treating various respiratory disorders; however, studies have also shown concomitant pitfall in delivery inefficiency. The aim of the study was to compare our novel polymeric vibrating-mesh nebulizer (μMVN+) to currently used aerosol devices during MV. Key word: aerosol drug delivery; vibrating-mesh nebulizer; small volume jet nebulizer; bronchodilator; mechanical ventilation.
Poster accepted for TSRT (Taiwan Society for Respiratory Therapy) Educational Conference 2017
Yu-Yao Kao, Chi-Shan Hung, Yu-Chung Hsu, Chia-Chen Huang, Wan-Cheng Tang, Kai-Yao Lo, Eric Y.T. Chen, Hui-Ling Lin
Abstract
Aerosol drug delivery through mechanical ventilation is pervasively applied to hospitalized patients in intensive care unit, respiratory care center and ward. Current delivery method heavily relies on small volume jet nebulizers (SVN). Despite its low cost, it severely suffers from general inefficiency due to high residual volume; troublesome operation instigated by drug dilution; requirement of additional gas supply; and significantly reduced drug delivery efficacy. In order to resolve existing dilemma, we have developed a new vibrating-mesh nebulizer specifically for mechanical ventilation system, the MicroBase mechanical ventilation nebulizer (μMVN). The purpose of this study was to compare the efficacy of μMVN and a SVN on delivering to drugs by placed at two locations.
-and-Jet-Nebulizer-at-Two-Locations-in-Adult-Mechanical-Ventilator_TWRC-poster.jpg)
Aerosol drug delivery through mechanical ventilation is pervasively applied to hospitalized patients in intensive care unit, respiratory care center and ward. Current delivery method heavily relies on small volume jet nebulizers (SVN). Despite its low cost, it severely suffers from general inefficiency due to high residual volume; troublesome operation instigated by drug dilution; requirement of additional gas supply; and significantly reduced drug delivery efficacy. In order to resolve existing dilemma, we have developed a new vibrating-mesh nebulizer specifically for mechanical ventilation system, the MicroBase mechanical ventilation nebulizer (μMVN). The purpose of this study was to compare the efficacy of μMVN and a SVN on delivering to drugs by placed at two locations.
Poster accepted for 19th Nano Engineering and Microsystem Technology Conference 2015
Lucas Ting-Kai Tsai, Sheng-Kai Lin, Shen-Hao Lai, Wei-Chun Chin, Eric Yi-Tong Chen
Abstract
Since its establishment on May 12th 1997, MicroBase Technology Corp. has been devoting to the development of Laser LIGA, a non-silicon based micromachining technology. The research & development and manufacture of miniaturized devices, micron-scale parts and systems are our core competencies, with significant success in the area of patent application. Currently MicroBase is the only company in the Asia-Pacific region with the capabilities of laser material processing, micro-electroforming development and mass production all in one.
By utilizing the laser material processing and micro-electroforming technology, Microbase developed the Micro Hole platform and applied the micro mesh technique to drug delivery in inhaled therapies. We are dedicated to providing a safe, efficient and convenient drug delivery system to healthcare professionals.
Besides our own drug delivery devices, we are also actively seeking opportunities to work with pharmaceutical companies to develop combination products.
Since its establishment on May 12th 1997, MicroBase Technology Corp. has been devoting to the development of Laser LIGA, a non-silicon based micromachining technology. The research & development and manufacture of miniaturized devices, micron-scale parts and systems are our core competencies, with significant success in the area of patent application. Currently MicroBase is the only company in the Asia-Pacific region with the capabilities of laser material processing, micro-electroforming development and mass production all in one.
By utilizing the laser material processing and micro-electroforming technology, Microbase developed the Micro Hole platform and applied the micro mesh technique to drug delivery in inhaled therapies. We are dedicated to providing a safe, efficient and convenient drug delivery system to healthcare professionals.
Besides our own drug delivery devices, we are also actively seeking opportunities to work with pharmaceutical companies to develop combination products.